The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAFV600E Mutation

被引：7
|
作者：
Anekpuritanang, Tauangtham [1 ]
Uataya, Maythad [2 ]
Claimon, Apichaya [3 ]
Laokulrath, Natthawadee [1 ]
Pongsapich, Warut [2 ]
Pithuksurachai, Paveena [2 ]
机构：
[1] Mahidol Univ, Fac Med, Dept Pathol, Siriraj Hosp, Bangkok 10700, Thailand
[2] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Otorhinolaryngol, 2 Wanglang Rd, Bangkok 10700, Thailand
[3] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Radiol, Bangkok 10700, Thailand
来源：
ONCOTARGETS AND THERAPY | 2021年 / 14卷
关键词：
BRAF mutation; immunohistochemistry; papillary thyroid carcinoma; radioiodine therapy; sodium/iodide symporter; BRAF V600E MUTATION; NA+/I-SYMPORTER; IODINE INTAKE; CANCER; NIS; MANAGEMENT; PROGNOSIS; NODULES; TISSUES; TUMORS;
D O I：
10.2147/OTT.S308910
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Objective: To study the association between radioiodine refractory papillary thyroid carcinoma, sodium/iodide symporter (NIS) expression, and the BRAF(V)(600E) mutation. Methods: A study was conducted on 30 radioiodine refractory papillary thyroid carcinoma patients and 30 radioiodine-avid papillary thyroid carcinoma patients. The expressions of sodium/iodide symporter and BRAF(V)(600E) mutated protein were determined by immunohistochemistry using formalin-fixed, paraffin-embedded tissue. Results: The mutated BRAF(V)(600E) protein was identified in 26 radioiodine refractory papillary thyroid carcinoma subjects (86.7%) and 22 radioiodine-avid papillary thyroid carcinoma subjects (73.3%), with no significant difference between the 2 groups (P = 0.3). Sodium/iodide symporter expression was detected in 4 of 30 cases (13.3%) from the radioiodine-avid papillary thyroid carcinoma group but was negative for all radioiodine refractory cases. There was no association between sodium/iodide symporter expression and radioiodine refractory papillary thyroid carcinoma (P = 0.11). Cases with positive NIS expression were likely negative for BRAF(V)(600E )mutation (3/4; P = 0.02). Conclusion: Papillary thyroid carcinomas with BRAF(V)(600E) mutation were more likely to be negative for NIS expression. BRAF(V)(600E) mutation and NIS expressions cannot be used to predict radioiodine sensitivity.
引用
收藏
页码：3959 / 3969
页数：11
相关论文
共 50 条
  • [21] Association between the BRAFV600E mutation and ultrasonographic features in papillary thyroid carcinoma: a study of 131 Chinese cases
    Zhang, Zheng
    Zhao, Shuang-Shuang
    Ding, Wen-Bo
    Zhang, Xin
    Wu, Xin-Cai
    Du, Rui
    Shang, Meng-Yuan
    Chen, Zhe-Ming
    Yu, Zhuan
    Chen, Bao-Ding
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (02): : 1929 - 1935
  • [22] BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic
    Sykorova, V.
    Dvorakova, S.
    Ryska, A.
    Vcelak, J.
    Vaclavikova, E.
    Laco, J.
    Kodetova, D.
    Kodet, R.
    Cibula, A.
    Duskova, J.
    Hlobilkova, A.
    Astl, J.
    Vesely, D.
    Betka, J.
    Hoch, J.
    Smutny, S.
    Cap, J.
    Vlcek, P.
    Novak, Z.
    Bendlova, B.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2010, 33 (05) : 318 - 324
  • [23] Is BRAFV600E mutation a marker for central nodal metastasis in small papillary thyroid carcinoma?
    Lang, Brian Hung-Hin
    Chai, Young Jun
    Cowling, Benjamin J.
    Min, Hye Sook
    Lee, Kyu Eun
    Youn, Yeo-Kyu
    ENDOCRINE-RELATED CANCER, 2014, 21 (02) : 285 - 295
  • [24] BRAFv600E mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma
    Jing Fan-jing
    Liang Jun
    Liang Zhi-yong
    Meng Chao
    Long Wen
    Li Xiao-yi
    Lin Yan-song
    CHINESE MEDICAL JOURNAL, 2013, 126 (16) : 3013 - 3018
  • [25] Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
    Huang, Shuhui
    Qi, Mengfang
    Tian, Tian
    Dai, Hongyuan
    Tang, Yuan
    Huang, Rui
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [26] BRAFV600E Mutation Analysis in Papillary Thyroid Carcinoma: Is it Useful for all Patients?
    Ito, Yasuhiro
    Yoshida, Hiroshi
    Kihara, Minoru
    Kobayashi, Kaoru
    Miya, Akihiro
    Miyauchi, Akira
    WORLD JOURNAL OF SURGERY, 2014, 38 (03) : 679 - 687
  • [27] Retrospective study of BRAFV600E mutation and CT features of papillary thyroid carcinoma
    Hong, Xiaoquan
    Li, Juxiang
    Duan, Shaoyin
    You, Youkuang
    PEERJ, 2024, 12
  • [28] Thyroid fine needle aspiration, the Bethesda System and the BRAFV600E mutation in Papillary Thyroid Carcinoma. Association and prediction for biopsy
    Galan-Garcia, Maria Eugenia
    Martinez-Martin, Maria Soledad
    Araujo-Ruano, Eduardo Jose
    Loro-Ferrer, Juan Francisco
    Saavedra-Santana, Pedro
    Salido-Ruiz, Eduardo
    Cabrera-Galvan, Juan Jose
    ACTA CYTOLOGICA, 2023, 67 (04) : 346 - 356
  • [29] The relationship between the BRAFV600E mutation in papillary thyroid microcarcinoma and clinicopathologic factors
    Sun Yi Choi
    HeonSoo Park
    Myung Koo Kang
    Dong Kun Lee
    Kang Dae Lee
    Hyoung Shin Lee
    Sung Won Kim
    Eun Nam Lee
    Jong Chul Hong
    World Journal of Surgical Oncology, 11
  • [30] BRAFV600E Mutation in Papillary Thyroid Carcinoma: Significant Association with Node Metastases and Extra Thyroidal Invasion
    Chakraborty, Avik
    Narkar, Archana
    Mukhopadhyaya, Rita
    Kane, Shubhada
    D'Cruz, Anil
    Rajan, M. G. R.
    ENDOCRINE PATHOLOGY, 2012, 23 (02) : 83 - 93
12345